When was Monopar Therapeutics founded?

Monopar Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Monopar Therapeutics located?

Monopar Therapeutics is headquartered in Wilmette, United States. It is registered at Wilmette, Illinois.

How many employees does Monopar Therapeutics have?

As of Sep 30, 2026, the latest employee count at Monopar Therapeutics is 27.

Is Monopar Therapeutics a funded company?

Monopar Therapeutics is a funded company, having raised a total of $11.8M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 10, 2015.

When was the latest funding round of Monopar Therapeutics?

Monopar Therapeutics' latest funding was a $***** Series A round on Nov 14, 2017, with participation from 0 investor.

Where does Monopar Therapeutics rank among its competitors?

Monopar Therapeutics ranks 436th amongst 2597 active competitors, of which 895 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Monopar Therapeutics?

Monopar Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Monopar Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of small molecules and antibodies for the treatment of cancers. The company's product Validive is a clonidine mucobuccal tablet is for the prevention and treatment of severe oral mucositis. Other compounds, MNPR-201, a doxorubicin analog, selective topoisomerase-IIα inhibitor, an alternative to cardiotoxic anthracycline-based cancer drugs, and MNPR-101 a humanized monoclonal antibody to the urokinase plasminogen activator receptor for the treatment of advanced cancers.

Website: www.monopartx.com/
Email ID: *****@monopartx.com
Phone Number: +1 **********
Registered Address: Wilmette, Illinois

Key Metrics

Founded Year

2014

Location

Wilmette, United States

Stage

Public

Total Funding

$11.8M in 2 rounds

Latest Funding Round

Series A, Nov 14, 2017, $*****

Investors

Hendricks Holding

Ranked

436^th among 2597 active competitors

Employee Count

27 as on Sep 30, 2026

Investment & Acquisitions

Gem Pharmaceuticals

Similar Companies

RayzeBio & 322 more

Exit Details

Public

View Monopar Therapeutics' full profile

Monopar Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Monopar Therapeutics Inc CIN: 830941217 , France, Deadpooled	Jul 18, 2017	-	-	-
MONOPAR THERAPEUTICS CIN: 1645469 , United States, Active	Dec 04, 2014	-	-	-
Monopar Therapeutics, Inc. CIN: 320463781 , United States, Active	Dec 26, 999	-	11 (As on Dec 31, 2024)	-

Monopar Therapeutics got listed on Dec 19, 2019.

Click here to take a look at Monopar Therapeutics's IPO in detail

Monopar Therapeutics has raised a total funding of $11.8M over 2 rounds. Its first funding round was on Jun 10, 2015. Monopar Therapeutics has 1 institutional investor.

Here is the list of recent funding rounds of Monopar Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 14, 2017	3765447	Series A	3957260	9909835	1651905	4242400
Jun 10, 2015	2034330	Series A	6883050	6632438	5532719	8085247

Access funding benchmarks and valuations. Sign up today!

View details of Monopar Therapeutics's funding rounds and investors

The founders of Monopar Therapeutics are Christopher Starr and Andrew Mazar.

Here are the details of Monopar Therapeutics' key team members:

Christopher Starr: Co-Founder & Chairman of Monopar Therapeutics.
Contact Info: 1 email address
Andrew Mazar: Co-Founder & VP of Monopar Therapeutics.

View details of Monopar Therapeutics's Founder profiles and Board Members

Monopar Therapeutics' employee count trend

Monopar Therapeutics has 27 employees as of Sep 26. Here is Monopar Therapeutics's employee count trend over the years:

Employee count trend for Monopar Therapeutics

Uncover Monopar Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Monopar Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Monopar Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
436th	Monopar Therapeutics 2014, Wilmette (United States), Public	Developer of small molecules and antibodies for the treatment of cancers	$11.8M	Hendricks Holding	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Monopar Therapeutics's competitors? Click here to see the top ones

Monopar Therapeutics has acquired Gem Pharmaceuticals. Monopar Therapeutics has not made any investments as of now.

Here is the latest report on Monopar Therapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Monopar Therapeutics

Media has covered Monopar Therapeutics for a total of 20 events in the last 1 year, 12 of them have been about company updates and 1 about people movement.